Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 9/20 | 0.46 |
| ▸ | PDE4A | P27815 | 8/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.31 |
| ▸ | STK10 | O94804 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL7250284 | 0.97 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6603711 | 0.85 | LMNA (0.41) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6608366 | 0.84 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6607899 | 0.83 | KDM4E (0.41) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6604186 | 0.82 | ALDH1A1 (0.42) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6601913 | 0.81 | LMNA (0.41) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6601910 | 0.81 | LMNA (0.41) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6601911 | 0.81 | LMNA (0.41) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL14473028 | 0.81 | LMNA (0.39) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6602566 | 0.80 | LMNA (0.34) | PDE4DPDE4APDE4BPDE4CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110961-B1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20030100772-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1264829-A1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-6376535-B2 | PHOSPHODIESTERASE (PDE) INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1110961-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | CBR1, CBR3, MT-CO1 | PDE4D 3411/4885PDE4A 2844/4885PDE4B 2596/4885 |
| US-20030100772-A1 | Oxygen-containing heterocyclic compounds | CBR1, CYP11B2, CBR3 | PDE4D 3430/4885PDE4A 2849/4885PDE4B 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.